Key result
Mineralocorticoid receptor antagonists are recommended for primary aldosteronism, driving ~10% of secondary hypertension.
Answers are grounded in this paper and cite their sources.
Aldosterone is increasingly considered to have a fundamental role in the pathophysiology of cardiovascular disease. Primary aldosteronism is a much more common cause of secondary hypertension than once suspected, accounting for approximately 10% of cases. Screening for primary aldosteronism should be considered even in the presence of normokalaemia. The non-classical effects of aldosterone, some of which are transcription-independent, may be of similar or greater importance than its traditional effects on the kidney. Treatment of primary aldosteronism should be specific and aim to ameliorate all hormone-related effects of aldosterone, not just the most obvious manifestation of hypertension. Mineralocorticoid antagonism, shown to lead to significant additional survival advantage in heart failure, offers the best prospect for achieving therapeutic goals. For the increasing proportion of patients with primary aldosteronism suitable for long-term medical treatment, mineralocorticoid receptor blockade (better tolerated with eplerenone) should be considered the most appropriate choice of treatment, pending the development of better alternatives.
No takes yet. Share an insight, caveat, or question.
Janmohamed et al. (2006) conducted a review in Primary aldosteronism and secondary hypertension. Mineralocorticoid receptor blockade (e.g., eplerenone) was evaluated. Mineralocorticoid receptor blockade (such as eplerenone) is recommended for primary aldosteronism, which accounts for approximately 10% of secondary hypertension cases.
Synapse has enriched 10 related papers. Consider them for comparative context: